Brief: Panbela Announces Positive Preclinical Data Strongly Supporting The Activity Of Sbp-101 In Ovarian Cancer Cell Lines Development Program For Sbp-101’S Expansion Into Ovarian Cancer Expected In 1H 2022
14/12/2021 14:12
Dec 14 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA ANNOUNCES POSITIVE PRECLINICAL DATA STRONGLY
SUPPORTING
THE ACTIVITY OF SBP-101 IN OVARIAN CANCER CELL LINES;
DEVELOPMENT PROGRAM FOR SBP-101’S EXPANSION INTO OVARIAN CANCER
EXPECTED IN 1H 2022
Source text for Eikon: ID:nGNX25kfHL
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants